Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis
- PMID: 18335564
- DOI: 10.1002/ajh.21180
Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis
Abstract
Denileukin diftitox (Ontak) is an immunotoxin used in the treatment of cutaneous T-cell lymphomas. Vascular leak syndrome is a known complication of this therapy, although the syndrome is most often self-limited. We report the case of a patient with cutaneous gamma/delta (gammadelta) T-cell lymphoma and previous undiagnosed liver disease treated with denileukin diftitox. Just 4 days after initiating drug therapy, the patient developed profound vascular leak syndrome characterized by a rapid fall in his previously normal serum albumin to levels below the limit of detection. The patient then quickly deteriorated into rhabdomyolysis and eventual death. To our knowledge, this is the first report of a death directly related to denileukin diftitox therapy. The purpose of this case is to increase awareness and improve management of patients who are treated with denileukin diftitox with resulting vascular leak syndrome leading to hypoalbuminemia.
(c) 2008 Wiley-Liss, Inc.
Similar articles
-
Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.Br J Dermatol. 2006 May;154(5):988-91. doi: 10.1111/j.1365-2133.2006.07151.x. Br J Dermatol. 2006. PMID: 16634908
-
Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):180-5. doi: 10.1016/j.clml.2012.01.011. Epub 2012 Apr 21. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22521504 Clinical Trial.
-
Optimizing denileukin diftitox (Ontak) therapy.Future Oncol. 2008 Aug;4(4):457-69. doi: 10.2217/14796694.4.4.457. Future Oncol. 2008. PMID: 18684057 Review.
-
Denileukin diftitox.Am J Clin Dermatol. 2000 Jan-Feb;1(1):67-72; discussion 73. doi: 10.2165/00128071-200001010-00008. Am J Clin Dermatol. 2000. PMID: 11702307 Review.
-
Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).Clin Lymphoma. 2002 Mar;2(4):222-8. doi: 10.3816/clm.2002.n.003. Clin Lymphoma. 2002. PMID: 11970761 Clinical Trial.
Cited by
-
The Effect of Small Molecule Pharmacological Agents on the Triterpenoid Saponin Induced Endolysosomal Escape of Saporin and a Saporin-Based Immunotoxin in Target Human Lymphoma Cells.Biomedicines. 2021 Mar 15;9(3):300. doi: 10.3390/biomedicines9030300. Biomedicines. 2021. PMID: 33804080 Free PMC article.
-
Harnessing the immune system in the treatment of cutaneous T cell lymphomas.Front Oncol. 2023 Jan 12;12:1071171. doi: 10.3389/fonc.2022.1071171. eCollection 2022. Front Oncol. 2023. PMID: 36713518 Free PMC article.
-
Nonhuman Primate Testing of the Impact of Different Regulatory T Cell Depletion Strategies on Reactivation and Clearance of Latent Simian Immunodeficiency Virus.J Virol. 2020 Sep 15;94(19):e00533-20. doi: 10.1128/JVI.00533-20. Print 2020 Sep 15. J Virol. 2020. PMID: 32669326 Free PMC article.
-
Inhibition of FOXP3 by stapled alpha-helical peptides dampens regulatory T cell function.Proc Natl Acad Sci U S A. 2022 Oct 18;119(42):e2209044119. doi: 10.1073/pnas.2209044119. Epub 2022 Oct 13. Proc Natl Acad Sci U S A. 2022. PMID: 36227917 Free PMC article.
-
Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma.Cancer Manag Res. 2010 Feb 5;2:53-9. doi: 10.2147/cmar.s5009. Cancer Manag Res. 2010. PMID: 21188096 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
